Figure 6.

LncRNA-SARCC suppressed RCC cell progression through altering AR in orthotopic xenografts. (a) Representative images of mice viewed by IVIS Lumina II system in shRNA-SARCC and shRNA-control group 4 weeks after left renal capsule injections (n=8). (b) Macroscopic appearance of the tumor xenografts in nude mice from the 7- to 8-week group with OSRC-2 cells with or without shRNA-SARCC (upper). Weights of the xenografts were also shown (mean±S.D.) (n=8) (lower). (c) Presented are representative images of abdominal metastasis viewed by IVIS Lumina II system in each group 4 weeks after the orthotopic xenograft transplantation (n=8). (d) Macroscopic appearance and representative images of metastatic organs viewed by IVIS in shRNA-SARCC and shRNA-control transfected OSRC-2 cells 4 weeks after left renal capsule injections (n=8). Quantitations shown in lower panel. (e) Macroscopic appearance of the tumor xenograft in nude mice from the 8- to 9-week group with OSRC-2 xenografts (upper). Weights of the xenografts were shown (mean±S.D.) (n=8) (lower). (f) Orthotopic xenograft animal models were also generated using mock, oe-AR, oeRNA-SARCC and oeRNA-SARCC+ oe-AR transfected OSRC-2 cells. Presented are representative images (left) of abdominal metastasis viewed by IVIS in each group 4 weeks after the orthotopic xenograft transplantation (n=8). Quantitations shown at right. (g) A schematic illustration of the proposed model depicting LncRNA-SARCC inhibits the invasion, migration and proliferation of renal cell carcinoma cells through modulating AR/miR-143-3p signals. Data shown are mean ± S.D. (n=8). For a, c, d, e, h, and i, *P<0.05